Judge Trims FTC's Pay-For-Delay Suit Against AbbVie
By Matthew Bultman (May 6, 2015, 7:30 PM EDT) -- Teva Pharmaceuticals USA Inc. didn't violate federal antitrust law when it struck a deal with AbbVie Inc. and others to end patent infringement litigation, a Pennsylvania federal judge ruled Wednesday, dismissing part of the Federal Trade Commission's pay-for-delay lawsuit over testosterone drug AndroGel.
U.S. District Judge Harvey Bartle III said the settlement Teva reached with AbbVie and its partners wasn't anti-competitive and didn't fit the definition of a so-called reverse payment under a landmark U.S. Supreme Court ruling.
The watchdog agency had also accused Teva of settling the lawsuit when it knew the case was groundless, a position Judge Bartle said...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!